Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Wirth

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|April 21, 2026
Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphomaBelinda A Campbell, Adrian Minson, Rachel J Brown, et al.
British Journal of Haematology|August 22, 2009
Mantle cell lymphoma with central nervous system involvement: frequency and clinical featuresSaar Gill, Kirsten E Herbert, H Miles Prince, et al.
BMJ Open|September 28, 2021
Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective studyNicole K Kiss, Linda Denehy, Lara Edbrooke, et al.
Leukemia & Lymphoma|February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology GroupAndrew Wirth, Andrew Grigg, Max Wolf, et al.
European Journal of Haematology. Supplementum|July 13, 2005
Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, ItalyPeter Mauch, Andrea Ng, Berthe Aleman, et al.
Physical and Engineering Sciences in Medicine|July 3, 2020
Total body irradiation in Australia and New Zealand: results of a practice surveyLotte S Fog, Andrew Wirth, Michael MacManus, et al.
European Journal of Clinical Nutrition|November 29, 2024
Sociodemographic and clinical factors associated with low muscle mass and composition in people treated with (chemo)radiotherapy for lung cancerNicole Kiss, Carla M Prado, Gavin Abbott, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2021
PET-Based Staging Is Cost-Effective in Early-Stage Follicular LymphomaAndrea C Lo, Lyndon P James, Anca Prica, et al.
Leukemia & Lymphoma|April 5, 2018
Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapyChelsea C Pinnix, Andrew Wirth, Sarah A Milgrom, et al.
The Lancet. Oncology|February 17, 2019
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trialDavid Ball, G Tao Mai, Shalini Vinod, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|April 21, 2026
Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphomaBelinda A Campbell, Adrian Minson, Rachel J Brown, et al.
British Journal of Haematology|August 22, 2009
Mantle cell lymphoma with central nervous system involvement: frequency and clinical featuresSaar Gill, Kirsten E Herbert, H Miles Prince, et al.
BMJ Open|September 28, 2021
Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective studyNicole K Kiss, Linda Denehy, Lara Edbrooke, et al.
Leukemia & Lymphoma|February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology GroupAndrew Wirth, Andrew Grigg, Max Wolf, et al.
European Journal of Haematology. Supplementum|July 13, 2005
Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, ItalyPeter Mauch, Andrea Ng, Berthe Aleman, et al.
Physical and Engineering Sciences in Medicine|July 3, 2020
Total body irradiation in Australia and New Zealand: results of a practice surveyLotte S Fog, Andrew Wirth, Michael MacManus, et al.
European Journal of Clinical Nutrition|November 29, 2024
Sociodemographic and clinical factors associated with low muscle mass and composition in people treated with (chemo)radiotherapy for lung cancerNicole Kiss, Carla M Prado, Gavin Abbott, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2021
PET-Based Staging Is Cost-Effective in Early-Stage Follicular LymphomaAndrea C Lo, Lyndon P James, Anca Prica, et al.
Leukemia & Lymphoma|April 5, 2018
Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapyChelsea C Pinnix, Andrew Wirth, Sarah A Milgrom, et al.
The Lancet. Oncology|February 17, 2019
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trialDavid Ball, G Tao Mai, Shalini Vinod, et al.
Pageof 8